Pustulotic arthro-osteitis (Sonozaki Syndrome)

Su, Özlem; Pirmit, Serpil; Özkaya, Dilek Bıyık; Kural, Yasemin Balsever; Onsun, Nahide

doi:10.4103/0019-5154.80417

Cited by 4 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a few case reports, elevated CRP levels were noted among patients with PAO 4,36,37 and lowering in CRP level was associated with alleviating symptoms of PAO. Findings from our study show no clear correlation between improvements in MRI scores and CRP levels.…”

Section: Discussionmentioning

confidence: 98%

“…To date, the literature for PAO is sparse, limited mostly to case reports or small case series, and there is a lack of well‐documented clinical studies 4,10,12,36,37 . In a study including 10 patients with PAO treated weekly with granulocyte and monocyte adsorption apheresis over 5 weeks, improvement in joint symptoms in 5/10 patients was demonstrated 38 .…”

Section: Discussionmentioning

confidence: 99%

“…Lesions are located exclusively, and often symmetrically, on the palms and/or soles. Association of PPP with bone and joint pain was first reported in Japan by Ishibashi et al 3 Pustulotic arthro‐osteitis (PAO), first described by Sonozaki et al and alternatively termed Sonozaki syndrome, 2,4 is a chronic disease characterized by an inflammatory osteitis of the sternoclavicular joint associated with PPP 2,5 . Other clinical manifestations of PAO include inflammation of the spine, the sacroiliac joint and peripheral joints 2,5,6 .…”

Section: Introductionmentioning

confidence: 99%

“…Treatment for PAO is usually pursued for symptomatic relief and consists of non‐steroidal anti‐inflammatory drugs and systemic cyclosporine 4,9–12 . Given that PAO may be associated with focal infection, treatment of underlying focal infection such as tonsillectomy may be considered 2,5 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis

Yamamoto

Fukuda

Morita

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque-type psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis (PPP). Objective The aim of this exploratory analysis of a double-blind, multicenter, placebo-controlled, phase 3 study in Japanese patients with PPP was to evaluate the efficacy of guselkumab in the subset of patients with pustulotic arthroosteitis (PAO). Methods Patients were randomized to receive guselkumab 100 or 200 mg at weeks 0, 4, 12 and every 8 weeks, or placebo with cross-over to guselkumab 100 or 200 mg at week 16 (placebo group). Efficacy endpoints were changes from baseline in magnetic resonance imaging (MRI) score, EuroQOL-5 dimensions (EQ-5D) index score, EQ-5D pain/discomfort dimension score and C-reactive protein (CRP, mg/L) level in all PAO patients through week 52. Data from both guselkumab groups were combined and presented as results for a single overall guselkumab group. Results Among 159 patients with PPP, 66 with PAO were randomized across treatment groups. For patients with MRI data for all regions assessed, the proportion of patients in the guselkumab group with PAO characterized as severe decreased from 23.8% (10/42) at baseline to 5.4% (2/42) at week 52. The mean (SD) change from baseline at week 52 in EQ-5D index score was 0.20 (0.17) among PPP patients with PAO and 0.15 (0.17) among those without PAO in the guselkumab group. Among all PAO patients, the proportions with an EQ-5D pain/discomfort dimension score of no or slight pain/ discomfort in the guselkumab group increased from baseline to week 52 [33.3% (7/21) vs. 87.5% (35/40)]. The mean (SD) CRP levels decreased in all PAO patients in the guselkumab group at week 52 compared to baseline [À1.71 (8.16) mg/L]. Conclusion Guselkumab treatment showed beneficial outcomes for PAO signs and symptoms in Japanese patients with PPP.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis

Yamamoto

Fukuda

Morita

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…The sternoclavicular joint involvement is uncommon in other spondyloarthropathies; thus, PAO differs from this group [9][10][11]. In our case, HLA-B27 was negative, sternoclavicular joint involvement was present, and there was no peripheral/sacroiliac joint involvement.…”

Section: Discussionmentioning

confidence: 69%

Pustulotic Arthro-Osteitis (Sonozaki Syndrome): A Case Report and Review of Literature

et al. 2018

View full text Add to dashboard Cite

Pustulotic arthro-osteitis (PAO) is a rare chronic inflammatory disease, which has now been classified as a seronegative spondyloarthritis. The sternoclavicular and sternocostal joints, pelvis, vertebra, hip, and long bones are affected. Skin findings of the disease are accepted as a variant of pustular psoriasis, but some authors have suggested that palmoplantar pustulosis (PPP) is a different entity. The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome should be considered in the differential diagnosis. PAO differs from SAPHO by the absence of hyperostosis and the difference in skin manifestations. Here, we aimed to present a 34-year-old female patient with a diagnosis of PAO with typical skin findings and joint involvement.

show abstract

Clinical characteristics of pustulotic arthro‐osteitis in Korea

Kim

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

Pustulotic arthro‐osteitis (PAO) has been studied primarily in Japan. However, there is a lack of research regarding its clinical features among large populations in other countries and it is often believed to be similar to psoriatic arthritis (PsA). Although the association between psoriasis (PsO) and palmoplantar pustulosis (PPP) is debatable, differences in the clinical characteristics between PsA and PAO might support the notion that PsO and PPP are distinct entities. This study aimed to investigate the clinical characteristics of PAO in Korean patients and to compare them with those of PsA. We retrospectively reviewed the medical records of patients diagnosed with PPP, PAO, and PsA. Among 266 patients with PPP, 13.2% had PAO. Unlike Japanese patients with PAO, Korean patients had a relatively lower involvement of the chest wall. PAO patients demonstrated lower age of onset, higher proportion of females, and higher severity of cutaneous eruptions compared to PPP patients without PAO, but the differences were not statistically significant. Female predominance was prominent in PAO compared to PsA. Cutaneous eruptions occurred earlier than joint symptoms in 83.5% of the patients with PsA and in 42.9% of the patients with PAO. PAO involved axial joints more frequently compared to PsA, especially the chest wall and spine. PsA mainly involved the peripheral joints, especially the metacarpophalangeal joints and distal interphalangeal joints of the hands and feet. In conclusion, PAO and PsA exhibited different demographics and locations of joint involvement, supporting the notion that PPP and PsO are separate disorders. Many PAO patients presented with joint symptoms before the appearance of skin eruptions, underlining the important role of dermatologists in recognizing PAO among PPP patients. Physicians should be aware of the characteristics of PAO while treating patients with PPP.

show abstract

Pustulotic arthro-osteitis (Sonozaki Syndrome)

Cited by 4 publications

References 9 publications

Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis

Efficacy of guselkumab in a subpopulation with pustulotic arthro‐osteitis through week 52: an exploratory analysis of a phase 3, randomized, double‐blind, placebo‐controlled study in Japanese patients with palmoplantar pustulosis

Pustulotic Arthro-Osteitis (Sonozaki Syndrome): A Case Report and Review of Literature

Clinical characteristics of pustulotic arthro‐osteitis in Korea

Contact Info

Product

Resources

About